Galectin Therapeutics
GALT
33 hedge funds and large institutions have $12.6M invested in Galectin Therapeutics in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
27% more funds holding
Funds holding: 26 → 33 (+7)
21% more capital invested
Capital invested by funds: $10.4M → $12.6M (+$2.21M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $556K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$1.88M |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$1.78M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$929K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$543K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.52M |
| 2 |
TFCP
Twin Focus Capital Partners
Boston,
Massachusetts
|
-$1.07M |
| 3 |
Neuberger Berman Group
New York
|
-$539K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$241K |
| 5 |
Jane Street
New York
|
-$100K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
First Manhattan
New York
| $13K | – | – | – |
|
|
OIA
27
Optimum Investment Advisors
Chicago,
Illinois
| $6K | – | – | – |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| $4K | -$241K | -26,072 | -98% |
|
29
AllianceBernstein
Nashville,
Tennessee
| $2K | – | – | – |
|
30
Citigroup
New York
| $2K | +$2.18K | +236 | New |
|
|
PSI
31
Pinnacle Summer Investments
Fairfax,
Virginia
| $1K | – | – | – |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$111 | +12 | +12% |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | +$1.45K | +157 | New |
|
|
EI
34
EAM Investors
Solana Beach,
California
| – | -$1.52M | -152,854 | Closed |
|
|
TFCP
35
Twin Focus Capital Partners
Boston,
Massachusetts
| – | -$1.07M | -107,363 | Closed |
|
|
36
Jane Street
New York
| – | -$100K | -10,076 | Closed |
|
|
SSG
37
Summit Securities Group
New York
| – | -$2K | -212 | Closed |
|
GALT Hedge Fund Activity: Q4 2013 in Review
33 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2013, worth a combined $12.6M — up 21% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GALT positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Catalyst Capital Advisors, opening a new position worth an estimated $1.88M. The largest seller was EAM Investors, exiting entirely with an estimated $1.52M sold.
- 33 institutional investors held Galectin Therapeutics (GALT) as of Q4 2013, up from 26 in Q3 2013.
- Funds reported $12.6M of Galectin Therapeutics stock for Q4 2013, up 21% quarter-over-quarter.
- 11 funds opened new Galectin Therapeutics positions in Q4 2013 and 4 closed out, a net change of +7 holders.
- The largest Galectin Therapeutics buyer in Q4 2013 was Catalyst Capital Advisors, an estimated $1.88M added.
- The largest Galectin Therapeutics seller in Q4 2013 was EAM Investors, an estimated $1.52M sold.
Based on aggregated 13F filings for Q4 2013.